<ul><li>Jefferies initiates coverage on Ajanta Pharma with a 'Buy' rating and a target price of Rs 2,850.</li><li>Ajanta Pharma has a strong positioning in high-entry-barrier branded generic markets in India, Asia, and Africa, which contribute around 70% of its revenue.</li><li>The company's recent foray into nephrology and gynaecology is expected to boost growth.</li><li>Overall, Jefferies expects Ajanta to report a 13% revenue CAGR, 17% Ebitda CAGR, and 19% profit CAGR over financial years 2025-27E.</li></ul>

Ajanta Pharma Positioned For Steady Growth; Jefferies Initiates Coverage With 'Buy'

Discover more